Applied Filters
Why Novartis lost its treatment dispute with Teva
The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.
Navigating the murky waters of the Hatch-Waxman ‘safe harbour’
Safe harbour provisions can be relied on but their boundaries are still being defined, explain Jeanna Wacker and Tasha Francis Gerasimow of Kirkland & Ellis.
Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox
Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.
Neurim, Flynn discover that time is not on their side
The case reinforced the need for interim injunction applications to be made as quickly as possible, explains Lydia Birch of EIP.
South Africa: homeopathy case clarifies ‘medicine’ definition
South Africa’s Supreme Court has declared regulations on complementary medicines invalid, explain Kareema Shaik and Jenny Pienaar of Adams & Adams.
When alliances fail, is arbitration the answer?
The global pandemic has increased collaboration and a new wave of disputes is likely. Arbitration is well placed to help, argue Kate Davies McGill, Gaela Gehring Flores and Paul Keller of Allen & Overy
NHS v Servier: unlawful means tort claim fails, but the long-running saga continues
The latest episode in the long-running dispute between the NHS and French pharmaceutical company Servier has been marked by a UK Supreme Court judgment of July 2, 2021 on Servier’s application to strike out the NHS’s unlawful means tort claim.
A new drug pricing system reform proposal in Japan
A Japanese think tank is recommending an overhaul of Japan’s drug pricing system. Takanori Abe of Abe and Partners reports.
UK experimental use exemptions: Part 3—the expanded exemption
In the third article of a four-part series on experimental use exemptions from infringement in the UK, Sophie Topham of Marks & Clerk considers the expansion of the original exemption.
UK experimental use exemptions: Part 2—the Bolar exemption
In the second of a four-part series, Sophie Topham of Marks & Clerk explains the rules around the exemption for studies, tests, and trials required for generic and biosimilar medicines.
